sorafenib — Medica

Initial criteria

• age ≥ 18 years
• relapsed or advanced disease
• clear cell histology
• tried at least one systemic therapy (e.g., axitinib, pazopanib, sunitinib, cabozantinib tablets)

Approval duration

1 year